Emerging therapies for fibromyalgia

Bibliography

• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33(2):160-72
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993;20(3):475-9
   PubMed Web of Science ®Google Scholar
• White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999;26(7):1570-6
   PubMed Web of Science ®Google Scholar
• Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005;75:6-21
   PubMedGoogle Scholar
• Wood PB, Holman AJ, Jones KD. Novel pharmacotherapy for fibromyalgia. Expert Opin Investig Drugs 2007;16(6):829-41
   PubMed Web of Science ®Google Scholar
• Busch A, Barber K, Overend T, et al. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007;17(4):CD003786
   Google Scholar
• Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res Ther 2006;8(4):R121
   PubMed Web of Science ®Google Scholar
• Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2006;2(8):416-24
   PubMedGoogle Scholar
• Thieme K, Turk DC, Flor H. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. Arthritis Rheum 2007;57(5):830-6
   PubMed Web of Science ®Google Scholar
• Redondo JR, Justo CM, Moraleda FV, et al. Long-term efficacy of therapy in patients with fibromyalgia: a physical exercise-based program and a cognitive-behavioral approach. Arthritis Rheum 2004;51(2):184-92
   PubMed Web of Science ®Google Scholar
• Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999;40(1):57-63.
   PubMed Web of Science ®Google Scholar
• Dadabhoy D, Clauw DJ. Therapy Insight: fibromyalgia – a different type of pain needing a different type of treatment. Nat Clin Pract Rheumatol 2006;2(7):364-72
   PubMedGoogle Scholar
• Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39(11):1852-9.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50(9):2974-84
   PubMed Web of Science ®Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32(10):1975
   PubMed Web of Science ®Google Scholar
• Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S. Alpha sleep characteristics in fibromyalgia. Arthritis Rheum 2001;44(1):222-30
   PubMed Web of Science ®Google Scholar
• Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):353-65
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP. The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry 2005;66(Suppl 2):14-20
   PubMed Web of Science ®Google Scholar
• Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26(7):793-9
   PubMed Web of Science ®Google Scholar
• Scharf M. Eszopiclone for the treatment of insomnia. Expert Opin Pharmacother 2006;7(3):345-56
   PubMed Web of Science ®Google Scholar
• Eszopiclone in the Treatment of Insomnia and Fibromyalgia. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT0039204
   Google Scholar
• Walsh JK, Moscovitch A, Burke J, et al. Efficacy and tolerability of indiplon in older adults with primary insomnia. Sleep Med 2007;8(7-8):753-9.
   PubMed Web of Science ®Google Scholar
• Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002;2:CD001520
   PubMedGoogle Scholar
• Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;[Epub ahead of print]
   Google Scholar
• Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999;26(12):2675-80
   PubMed Web of Science ®Google Scholar
• Press J, Phillip M, Neumann L, et al. Normal melatonin levels in patients with fibromyalgia syndrome. J Rheumatol 1998;25(3):551-5
   PubMed Web of Science ®Google Scholar
• Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000;19(1):9-13
   PubMed Web of Science ®Google Scholar
• Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther 2006;28(10):1540-55
   PubMed Web of Science ®Google Scholar
• Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003;30(5):1070-4
   PubMed Web of Science ®Google Scholar
• A Safety and Efficacy Study of Xyrem® (Sodium Oxybate); to Treat Fib. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT00423813
   Google Scholar
• Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007;14(335):7610
   Google Scholar
• Eisenberg E, River Y, Shifrin A, Krivoy N. Antiepileptic drugs in the treatment of neuropathic pain. Drugs 2007;67(9):1265-89
   PubMed Web of Science ®Google Scholar
• Stokes MJ, Colter C, Klestov A, Cooper RG. Normal paraspinal muscle electromyographic fatigue characteristics in patients with primary fibromyalgia. Br J Rheumatol 1993;32(8):711-6
   PubMedGoogle Scholar
• Ersoz M. Nerve conduction tests in patients with fibromyalgia: comparison with normal controls. Rheumatol Int 2003;23(4):166-70
   PubMed Web of Science ®Google Scholar
• No authors listed. Pregabalin (Lyrica) for fibromyalgia. Med Lett Drugs Ther 2007;24(49):1270
   Google Scholar
• Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):229-36
   PubMed Web of Science ®Google Scholar
• Bian F, Li Z, Offord J, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res Mol Brain Res 2006;1075(1):68-80
   Google Scholar
• Crofford Leslie J, Rowbotham Michael C, Mease Philip J, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(4):1264-73
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28(2):187-93
   PubMed Web of Science ®Google Scholar
• Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56(4):1336-44
   PubMed Web of Science ®Google Scholar
• Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 2005;19(1):35-43
   PubMedGoogle Scholar
• Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 2006;10(3):193-8
   PubMed Web of Science ®Google Scholar
• Bernstein CD, Diaz JH, Gould HJ 3rd. A possible role for zonisamide in treating neuropathic pain: a case of idiopathic polyneuropathy. Pain Pract 2002;2(2):134-6
   PubMedGoogle Scholar
• Levetiracetam for Treatment of Pain Associated With Fibromyalgia. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT00254657
   Google Scholar
• Zonisamide for Fibromyalgia & Migraine. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT00259636
   Google Scholar
• Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24(3):555-9
   PubMed Web of Science ®Google Scholar
• Yunus MB, Dailey JW, Aldag JC, et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992;19(1):90-4
   PubMed Web of Science ®Google Scholar
• Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998;59(Suppl 14):11-4
   PubMed Web of Science ®Google Scholar
• Vierck CJ Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain 2006;124(3):242-63
   PubMed Web of Science ®Google Scholar
• Lu Y, Perl ER. Selective action of noradrenaline and serotonin on neurones of the spinal superficial dorsal horn in the rat. J Physiol 2007;582(1):127-36.
   PubMed Web of Science ®Google Scholar
• O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15(9):659-66
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119(1-3):5-15
   PubMed Web of Science ®Google Scholar
• Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT00375973
   Google Scholar
• Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol Clin Exp 2004;19:S27-35
   PubMed Web of Science ®Google Scholar
• Cypress Bioscience, Inc.: compounds in trial statement. In; 2007. Available at: http://www.cypressbio.com/products/milnacipranPhase3.php
   Google Scholar
• Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome. In; 2007. Available at: http://www.frx.com/news/PressRelease.aspx?ID=1005671
   Google Scholar
• Study Evaluating the Efficacy of DVS-233 in Fibromyalgia. In; 2007. Available at: http://clinicaltrials.gov/ct/show/NCT00301431
   Google Scholar
• Malt EA, Olafsson S, Aakvaag A, et al. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003;75(1):77-82
   PubMed Web of Science ®Google Scholar
• Wood PB, Patterson JC 2nd, Sunderland JJ, et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8(1):51-8
   PubMed Web of Science ®Google Scholar
• Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25(12):3576-82
   PubMed Web of Science ®Google Scholar
• Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9(8):730-1
   PubMed Web of Science ®Google Scholar
• Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005;52(8):2495-505
   PubMed Web of Science ®Google Scholar
• Bliwise DL, Freeman A, Ingram CD, et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6(2):141-7
   PubMed Web of Science ®Google Scholar
• Holman AJ. Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia. J Clin Rheumatol 2003;94:277-9
   Google Scholar
• Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome – a preliminary study. J Rheumatol 1996;23(8):1418-23
   PubMed Web of Science ®Google Scholar
• Tolk J, Kohnen R, Müller W. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol Suppl 2004;119:72-5
   Google Scholar
• Seidel MF, Weinreich GF, Stratz T, Müller W. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27(11):1025-30
   PubMed Web of Science ®Google Scholar
• Rao SG. The neuropharmacology of centrally-acting analgesic medications in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):235-59
   PubMed Web of Science ®Google Scholar
• Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2004;25(1-2):31-9
   PubMed Web of Science ®Google Scholar
• Schley M, Legler A, Skopp G, et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006;22(7):1269-76
   PubMed Web of Science ®Google Scholar
• Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006;53(8):769-75
   PubMed Web of Science ®Google Scholar
• Wissel J, Haydn T, Müller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006;253(10):1337-41
   PubMed Web of Science ®Google Scholar
• A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia. In. Available at: http://clinicaltrials.gov/ct/show/NCT00272207
   Google Scholar
• Bagge E, Bengtsson BA, Carlsson L, Carlsson J. Low growth hormone secretion in patients with fibromyalgia – a preliminary report on 10 patients and 10 controls. J Rheumatol 1998;25(1):145-8
   PubMed Web of Science ®Google Scholar
• Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104(3):227-31
   PubMed Web of Science ®Google Scholar
• Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 2002;4(4):306-12
   PubMedGoogle Scholar
• Codner E, Cassorla F, Tiulpakov AN, et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther 2001;70(1):91-8
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia. In. Available at: http://clinicaltrials.gov/ct/show/NCT00116129
   Google Scholar
• Moulin A, Ryan J, Martinez J, Fehrentz JA. Recent developments in ghrelin receptor ligands. ChemMedChem 2007;2(9):1242-59
   PubMed Web of Science ®Google Scholar
• Cook DB, Lange G, Ciccone DS, et al. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31(2):364-78
   PubMed Web of Science ®Google Scholar
• Guedj E, Taieb D, Cammilleri S, et al. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging 2007;34(1):130-4
   PubMed Web of Science ®Google Scholar
• Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-01
   PubMed Web of Science ®Google Scholar
• Russell IJ. The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002;28(2):329-42
   PubMed Web of Science ®Google Scholar
• Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am 2007;36(1):37-55
   PubMed Web of Science ®Google Scholar
• Jones KD, Deodhar P, Lorentzen A, et al. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007;36(6):357-79
   PubMed Web of Science ®Google Scholar
• Ablin JN, Cohen H, Buskila D. Mechanisms of disease: genetics of fibromyalgia. Nat Clin Pract Rheumatol 2006;2(12):671-8
   PubMedGoogle Scholar
• Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42(11):2482-8
   PubMed Web of Science ®Google Scholar
• Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002;46(3):845-7
   PubMed Web of Science ®Google Scholar
• Camilleri M. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterol Motil 2007;19(Suppl 2):40-5
   PubMed Web of Science ®Google Scholar
• Camilleri M. Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics 2005;6(5):491-501
   PubMed Web of Science ®Google Scholar
• Kurland JE, Coyle WJ, Winkler A, Zable E. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci 2006;51(3):454-60
   PubMed Web of Science ®Google Scholar
• Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46(5):1333-43
   PubMed Web of Science ®Google Scholar
• Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52(5):1577-84
   PubMed Web of Science ®Google Scholar
• Wise RG, Tracey I. The role of fMRI in drug discovery. J Magn Reson Imaging 2006;23(6):862-76
   PubMed Web of Science ®Google Scholar
• Schweinhardt P, Bountra C, Tracey I. Pharmacological FMRI in the development of new analgesic compounds. NMR Biomed 2006;19(6):702-11
   PubMed Web of Science ®Google Scholar